Medipal Holdings announced an investment in mutex through its corporate venture capital fund. Reze is an AI-powered claims-processing support SaaS for healthcare institutions that aims to automate operations and support real-world implementation in the future.
Medipal Holdings invested in mutex through the MEDIPAL Innovation Investment Limited Partnership by participating in mutex's third-party allotment of new shares.
mutex's AI-powered claims-processing support SaaS for healthcare institutions, Reze, aims to improve operational efficiency and optimize revenue through claims review, generation of detailed symptom descriptions, and management of returned and assessed claims.
Reze began offering its service in July 2025 and is being developed toward the full automation of medical claims billing operations through AI agents.
Through the investment, Medipal Holdings is expected to promote mutex's system development and real-world implementation, contributing to the expansion of digital solutions in the medical DX field.